Novartis | NVS - Current Assets



Novartis reported $31.26B in Current Assets for its fiscal quarter ending in September of 2024.

Current Assets Change Date
AbbVie USD 27.78B 6.03B Sep/2024
Amgen USD 26.77B 440M Sep/2024
AstraZeneca USD 24.16B 1.24B Sep/2024
Bausch Health Companies USD 5.35B 140M Sep/2024
Biogen USD 6.83B 278M Sep/2024
Bristol-Myers Squibb USD 28.08B 1.18B Sep/2024
Canopy Growth CAD 357.79M 13.39M Jun/2024
Catalent USD 2.92B 410M Jun/2025
Corcept Therapeutics USD 466.98M 93.87M Sep/2024
Drreddys Laboratories INR 269.19B 21.14B Jun/2024
Eli Lilly USD 31.42B 1.21B Sep/2024
Gilead Sciences USD 13.06B 742M Sep/2024
GlaxoSmithKline GBP 17.3B 534M Sep/2024
Glaxosmithkline GBP 17.3B 93M Sep/2024
J&J USD 53.25B 4.57B Sep/2024
Merck USD 40.36B 2.16B Sep/2024
Novartis USD 31.26B 5.57B Sep/2024
Novartis USD 31.26B 4.82B Sep/2024
Pacira USD 689.97M 57.76M Sep/2024
Perrigo USD 3.71B 748.7M Sep/2024
Pfizer USD 37.83B 4.59B Jun/2024
Prestige Brands USD 380.71M 11.97M Sep/2024
Roche Holding CHF 33.63B 183M Jun/2024
Sanofi 30.08B 589M Jun/2024
Sanofi 30.08B 589M Jun/2024
Supernus Pharmaceuticals USD 640M 49M Sep/2024
Zoetis USD 6.28B 80M Sep/2024